Metronomic methotrexate and cyclophosphamide after carboplatin included adjuvant chemotherapy in triple negative breast cancer: a phase III study.

@article{Nasr2015MetronomicMA,
  title={Metronomic methotrexate and cyclophosphamide after carboplatin included adjuvant chemotherapy in triple negative breast cancer: a phase III study.},
  author={Khalid E. Nasr and Mohammed A. M. Osman and Mohammad S. Elkady and Mahmoud Mahmoud Abbass Ellithy},
  journal={Annals of translational medicine},
  year={2015},
  volume={3 19},
  pages={284}
}
BACKGROUND Despite being chemosensitive, the majority of triple negative breast cancer (TNBC) patients recur. The primary study objectives were to compare disease free survival (DFS), and overall survival (OS) for TNBC after adjuvant chemotherapy, who underwent maintenance metronomic chemotherapy versus no maintenance therapy. METHODS TNBC patients were eligible for enrolment if they had TNM stages II-III and fit with our inclusion criteria. Patients were assigned to either: group 1, 3 cycles… CONTINUE READING